Replies to post #61556 on Savvy Trades and Investments

[2morrowsGains]

SRTS...Lot of exciting things in the Sensus pipeline, that's for sure. Love the fact that they have low to no debt and the growth so far has been all organic. Looking forward to updates on Thursday.

Also, Re: ATOM. Thanks. IF/when Atomera hits the royalty phase with 1 or 2+ top chip makers, who knows where this could go. I don't really understand a lot of the verbiage, but I know enough that node performance improvement going from 18% to 50% should get lots of attention, especially if these semiconductor companies were already interested in an 18% improvement.
Time will tell. We'll see what happens. This is from the cc..."Now I do want to caution that this is 2-week-old data. We're just starting to share with customers."

[2morrowsGains]

SRTS...Nice news this morning...Sensus Healthcare Awarded Brachytherapy Products Agreement with Premier

Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in novel radiation oncology technologies and solutions, has been awarded a group purchasing agreement for Brachytherapy Products with Premier. Effective August 1, 2019, the new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for Sensus' SRT-100(TM) Superficial Radiation Therapy systems.

https://mma.prnewswire.com/media/571356/SENSUS_HEALTHCARE_Logo.jpg

"Premier is a well-established and respected organization," said Joe Sardano, CEO, Sensus Healthcare. "We are proud of our relationship with the company and its 4,000+ member hospitals and health systems and over 165,000 other providers."

SRT delivers precise, calibrated, low-dose radiation that effectively destroys basal and squamous cell carcinomas, as well as the non-malignant tumor cells that cause keloids. Each treatment is virtually painless and doesn't involve cutting, bleeding, stitching or anesthesia. There is also no risk of infection or scarring and no need for reconstructive plastic surgery. Sensus' SRT-100(TM) is cleared by the U.S. Food and Drug Administration (FDA) for the treatment of both non-melanoma skin cancers and keloids.

Premier is a leading healthcare improvement company, uniting an alliance of approximately 4,000 U.S. hospitals and 165,000 other providers to transform healthcare. With integrated data and analytics, collaboratives, supply chain solutions and advisory and other services, Premier enables better care and outcomes at a lower cost